CVKD

Cadrenal Therapeutics Inc

1.07

Sep 18 • 3:59 PM ET -0.05 (-4.46%)

1.10

Aftermarket • 7:30 PM ET +0.03 (2.80%)

Healthcare Biotechnology USA Nano NASD

Peers: CMMB COCP HCWB INAB LEXX MTVA XCUR HIND NCEL OSRH

| Held by: VTI VXF DFSU

Scroll to Statements

Index	-
Market Cap	3.82M
Enterprise Value	1.43M
Income	-11.54M
Sales	0.00M
Book/sh	1.32
Cash/sh	0.67
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	5
IPO	Jan 20, 2023

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.81
P/C	1.60
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	3.67
Current Ratio	3.67
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-4.90
EPS next Y	-3.01
EPS next Q	-0.91
EPS this Y	41.82%
EPS next Y	22.17%
EPS next 5Y	34.69%
EPS past 3/5Y	8.46% -
Sales past 3/5Y	- -
EPS Y/Y TTM	44.80%
Sales Y/Y TTM	-
EPS Q/Q	38.99%
Sales Q/Q	-
Earnings	Aug 13 AMC
EPS/Sales Surpr.	19.72% -

Insider Own	9.66%
Insider Trans	-22.07%
Inst Own	10.09%
Inst Trans	19.01%
ROA	-199.59%
ROE	-275.16%
ROIC	-282.13%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-19.23%
SMA50	-38.90%
SMA200	-78.88%
Trades

Shs Outstand	3.57M
Shs Float	3.22M
Short Float	2.70%
Short Ratio	0.20
Short Interest	0.09M
52W High	14.64 -92.69%
52W Low	1.00 7.00%
Volatility	6.98% 11.30%
ATR (14)	0.15
RSI (14)	26.40
Beta	1.95
Rel Volume	0.26
Avg Volume	431.81K
Volume	113,695

Perf Week	-1.83%
Perf Month	-34.76%
Perf Quarter	-69.43%
Perf Half Y	-84.65%
Perf YTD	-84.22%
Perf Year	-91.98%
Perf 3Y	-90.09%
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	14.00
Prev Close	1.12
Price	1.07
Change %	-4.46%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-18-23	Initiated	Noble Capital Markets	Outperform	$4

Sep-03-26 08:00AM	Cadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference (GlobeNewswire)
Aug-31-26 08:00AM	Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia (GlobeNewswire) +13.64%
Aug-13-26 04:15PM	Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process (GlobeNewswire)
Aug-03-26 08:30AM	Cadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor's Phase 3 Discontinuation (GlobeNewswire)
Jul-21-26 08:00AM	Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation (GlobeNewswire)
09:00AM	Loading…
Jul-13-26 09:00AM	Cadrenal Therapeutics' Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress (GlobeNewswire) -16.26%
Jun-30-26 08:00PM	Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) +10.60% -5.09%
Jun-24-26 08:00AM	Cadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 Congress (GlobeNewswire)
Jun-18-26 09:00AM	Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease (GlobeNewswire) +12.90%
Jun-15-26 08:30AM	Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026 (GlobeNewswire) -10.00%
Jun-03-26 09:00AM	Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Event (GlobeNewswire)
May-19-26 04:30PM	Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026 (GlobeNewswire)
May-07-26 08:30AM	Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA (GlobeNewswire)
Apr-30-26 08:30AM	Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT) (GlobeNewswire) +19.32%
Mar-31-26 08:45AM	Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting (GlobeNewswire) +20.47%
08:00AM	Loading…
Mar-12-26 08:00AM	Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes (GlobeNewswire) -7.95%
Mar-02-26 08:00AM	Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion (GlobeNewswire)
Feb-24-26 08:30AM	Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement (GlobeNewswire) +16.10%
Jan-12-26 08:00AM	Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX Inhibitor (GlobeNewswire)
Dec-30-25 08:00AM	Cadrenal's Pipeline Looks Less Like a Microcap and More Like an Emergency Response System (ACCESSWIRE)
Dec-29-25 08:00AM	Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On (ACCESSWIRE) -6.75%
Dec-17-25 09:00AM	Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026 (GlobeNewswire)
Dec-12-25 11:00AM	Cadrenal's Quiet Expansion Play Is Starting to Get Loud (ACCESSWIRE)
09:45AM	Cadrenal's Anticoagulation Platform Is Expanding in a $40 Billion Market (ACCESSWIRE)
Dec-11-25 08:05AM	Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT) (GlobeNewswire)
Dec-01-25 09:00AM	Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors (GlobeNewswire)
Nov-19-25 08:00AM	Cadrenal Therapeutics CEO, Quang X. Pham, Receives BioFlorida's Executive of the Year Award (GlobeNewswire) -5.61%
Nov-17-25 03:00PM	Why the underdog mindset could be your business superpower (Yahoo Finance Video)
Nov-10-25 09:00AM	Cadrenal Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-08-25 01:27AM	Cadrenal Therapeutics, Inc. (Zacks)
04:30PM	Loading…
Sep-29-25 04:30PM	Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025 (GlobeNewswire)
Sep-16-25 05:36AM	Cadrenal Therapeutics acquires eXItheras Factor XIa inhibitors (Pharmaceutical Technology)
Sep-15-25 08:00AM	Cadrenal Therapeutics Enhances Anticoagulation Pipeline Through Acquisition of eXIthera's Portfolio of Factor XIa Inhibitors (GlobeNewswire)
Aug-11-25 08:00AM	Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (Business Wire)
Aug-05-25 06:00AM	Cadrenal Therapeutics Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitioning to Dialysis (Business Wire) +23.72%
Jun-12-25 08:00AM	Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients (Business Wire)
Jun-04-25 08:00AM	Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025 (Business Wire) +13.15%
May-15-25 07:30AM	Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness (Business Wire) +7.07%
May-08-25 08:00AM	Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update (Business Wire)
Apr-17-25 09:40AM	Cadrenal Therapeutics to Present at Inaugural Centri Capital Conference at Nasdaq (Business Wire)
Apr-03-25 08:00AM	Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences (Business Wire)
Mar-13-25 04:05PM	Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin (Business Wire) +9.40%
Mar-05-25 07:28AM	Cadrenal and Abbott sign agreement for LVAD trial of tecarfarin (Medical Device Network)
Mar-04-25 08:00AM	Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3 LVAD (Business Wire)
Feb-06-25 09:00AM	Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin (Business Wire)
Feb-05-25 09:00AM	Cadrenal Therapeutics to Present at BIO CEO & Investor Conference (Business Wire)
Jan-09-25 08:44AM	Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 (Business Wire)
Dec-31-24 08:00AM	Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications (Business Wire)
Dec-18-24 09:00AM	Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings (Business Wire) +13.19%
Nov-19-24 09:00AM	Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook (PR Newswire) -7.29%
Nov-12-24 09:00AM	CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESS (PR Newswire)
Nov-07-24 09:00AM	CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE (PR Newswire)
Nov-01-24 08:00PM	Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds (PR Newswire) -18.86%
Oct-24-24 09:00AM	Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility (PR Newswire) +17.97%
Oct-23-24 09:00AM	CADRENAL THERAPEUTICS JOINS CORPORATE COUNCIL OF ANTICOAGULATION FORUM (PR Newswire)
Sep-23-24 04:15PM	Cadrenal Therapeutics to Participate in Lytham Partners Fall 2024 Investor Conference (PR Newswire) -12.17% +16.94%
Sep-11-24 01:00PM	Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing (ACCESSWIRE) +17.85%
Aug-22-24 09:00AM	Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients (PR Newswire) -5.52%
Aug-21-24 07:00AM	Presenting on the Emerging Growth Conference 74 Day 2 on August 22 Register Now (GlobeNewswire)
Aug-20-24 09:00AM	Published Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD Patients (PR Newswire) +19.12%
07:00AM	Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now (GlobeNewswire)
Aug-14-24 09:00AM	Cadrenal Therapeutics to Present at Upcoming Investor Conferences (PR Newswire)
Aug-12-24 05:07PM	Cadrenal Therapeutics, Inc. (CVKD): A New Penny Stock to Buy Now (Insider Monkey) +13.67%
Aug-07-24 11:53PM	CVKD Stock Earnings: Cadrenal Therapeutics Misses EPS for Q2 2024 (InvestorPlace)
04:05PM	Cadrenal Therapeutics Provides Second Quarter 2024 Corporate Update (PR Newswire)
Aug-06-24 09:00AM	Cadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for Patients with LVADs (PR Newswire)
Jul-17-24 09:00AM	Cadrenal Therapeutics to Present at the Emerging Growth Conference on July 18, 2024 (PR Newswire)
07:00AM	Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now (GlobeNewswire)
Jul-16-24 07:00AM	Presenting on the Emerging Growth Conference 73 Day 1 on July 17 Register Now (GlobeNewswire)
Jun-12-24 07:00AM	Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now (GlobeNewswire)
Jun-11-24 04:15PM	Cadrenal Therapeutics to Present at the Emerging Growth Conference on June 12, 2024 (PR Newswire) +6.34%
07:00AM	Presenting on the Emerging Growth Conference 72 Day 1 on June 12 Register Now (GlobeNewswire)
Jun-03-24 09:00AM	Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD Patients (PR Newswire) +5.45%
May-23-24 09:00AM	Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024 (PR Newswire)
May-09-24 01:53PM	CVKD Stock Earnings: Cadrenal Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
09:00AM	Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update (PR Newswire)
Apr-11-24 04:30PM	Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024 (PR Newswire) -5.34%
Apr-09-24 09:00AM	Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts (PR Newswire) -19.86%
Mar-11-24 09:00AM	Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update (PR Newswire)
Feb-26-24 09:00AM	Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference (PR Newswire)
Feb-08-24 09:00AM	Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial (PR Newswire) -19.47%
Jan-31-24 09:00AM	Cadrenal Therapeutics Highlights Publication of Peer-Reviewed Article Supporting Need for New Anticoagulation Therapy for Patients with Certain Medical Conditions (PR Newswire) +8.33%
Jan-24-24 09:00AM	Cadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024 (PR Newswire) +19.25%
Jan-04-24 09:00AM	Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare Conference (PR Newswire)
Dec-19-23 09:00AM	Noble Capital Markets Initiates Coverage on Cadrenal Therapeutics with Outperform Rating and US$4.00 Price Target (PR Newswire) +6.94%
Dec-12-23 09:00AM	Cadrenal Therapeutics Engages The Sage Group to Advance Tecarfarin's Late-Stage Development and Commercialization (PR Newswire)
Nov-30-23 04:15PM	Cadrenal Therapeutics to Present at the NobleCon 19 Conference on December 4, 2023 (PR Newswire) +8.70%
Nov-09-23 09:00AM	Cadrenal Therapeutics Provides Third Quarter 2023 Corporate Update (PR Newswire) -5.38%
Oct-16-23 08:38AM	Innovation Takes Center Stage: Florida's Life Sciences Leaders Shine at BioFlorida Conference (PR Newswire)
Oct-09-23 04:15PM	Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2023 Investor Conference (PR Newswire)
Sep-05-23 08:00AM	Cadrenal Therapeutics Highlights Additional Need for a New Vitamin K Antagonist (Tecarfarin) Following Updates from the Recent European Society of Cardiology Congress (PR Newswire)
Aug-30-23 08:00AM	Cadrenal Therapeutics Expands Evaluation of Tecarfarin for Patients with Antiphospholipid Syndrome (APS) (PR Newswire)
Aug-28-23 04:15PM	Cadrenal Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire)
Aug-10-23 09:00AM	Cadrenal Therapeutics Provides Second Quarter 2023 Corporate Update (PR Newswire)
Aug-01-23 09:00AM	Cadrenal Therapeutics Expands Focus for Tecarfarin to Patients with Implanted Medical Devices for Heart Diseases (PR Newswire)
Jul-24-23 09:00AM	Cadrenal Therapeutics Announces Appointment of Robert Lisicki to Board of Directors (PR Newswire) -11.65%
Jul-14-23 03:02PM	Cadrenal Therapeutics Announces Closing of $7.5 Million Private Placement Priced At-the-Market under Nasdaq Rules (PR Newswire) -18.37%
Jul-12-23 03:17PM	Cadrenal Therapeutics Announces $7.5 Million Private Placement Priced At-the-Market under Nasdaq Rules (PR Newswire) +29.31%
Jun-28-23 06:23AM	The 3 Hottest IPOs to Buy Before They Soar (InvestorPlace)
Jun-01-23 09:00AM	Cadrenal Therapeutics to Participate in the 2023 BIO International Convention in Boston (PR Newswire)

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Chairman & CEOMr. Quang X. Pham

Interim CFO & Principal Accounting OfficerMr. John P. Sharp CPA

Chief Operating OfficerMr. Jeffrey Cole

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Pham Quang X	Chairman and CEO	Jun 29 '26	Sale	3.03	7,400	22,422	98,589	Jul 01 09:52 PM
Pham Quang X	Chairman, CEO and Interim CFO	Jun 26 '26	Sale	3.05	9,029	27,538	105,989	Jun 26 08:44 PM
Pham Quang X	Chairman, CEO and Interim CFO	Jun 25 '26	Sale	3.00	2,127	6,381	115,018	Jun 26 08:44 PM
Pham Quang X	Chairman, CEO and Interim CFO	Jun 22 '26	Sale	3.55	9,167	32,543	119,422	Jun 24 05:15 PM
Pham Quang X	Chairman, CEO and Interim CFO	Jun 23 '26	Sale	3.20	2,277	7,286	117,145	Jun 24 05:15 PM
Pham Quang X	Chairman, CEO and Interim CFO	Jun 16 '26	Sale	3.18	3,613	11,489	129,102	Jun 18 06:36 PM
Pham Quang X	Chairman, CEO and Interim CFO	Jun 17 '26	Sale	3.16	513	1,621	128,589	Jun 18 06:36 PM
Pham Quang X	Chairman, CEO and Interim CFO	Jun 12 '26	Sale	3.94	12,996	51,204	136,381	Jun 15 08:58 PM
Pham Quang X	Chairman, CEO and Interim CFO	Jun 15 '26	Sale	3.58	3,666	13,124	132,715	Jun 15 08:58 PM
Pham Quang X	Chairman, CEO and Interim CFO	Jun 11 '26	Sale	4.12	1,462	6,023	149,377	Jun 15 08:58 PM
Quang X. Pham	Officer	Jun 15 '26	Proposed Sale	3.71	40,000	148,400		Jun 15 08:16 PM
Pham Quang X	Chairman, CEO and Interim CFO	Jun 09 '26	Sale	4.06	12,992	52,748	154,339	Jun 10 08:26 PM
Pham Quang X	Chairman, CEO and Interim CFO	Jun 08 '26	Sale	4.38	5,893	25,811	167,331	Jun 10 08:26 PM
Pham Quang X	Chairman, CEO and Interim CFO	Jun 10 '26	Sale	4.21	3,500	14,735	150,839	Jun 10 08:26 PM
Pham Quang X	CEO and Chairman	Jun 04 '26	Sale	4.41	3,898	17,190	175,288	Jun 05 05:26 PM
Pham Quang X	CEO and Chairman	Jun 03 '26	Sale	4.26	2,323	9,896	179,186	Jun 05 05:26 PM
Pham Quang X	CEO and Chairman	Jun 05 '26	Sale	4.42	2,064	9,123	173,224	Jun 05 05:26 PM
Pham Quang X	CEO and Chairman	Jun 02 '26	Sale	4.46	349	1,557	181,509	Jun 02 08:34 PM
Pham Quang X	CEO and Chairman	May 29 '26	Sale	5.01	303	1,518	181,858	Jun 02 08:34 PM
Pham Quang X	CEO and Chairman	May 11 '26	Sale	5.76	6,476	37,302	188,448	May 29 04:30 PM
Pham Quang X	CEO and Chairman	May 12 '26	Sale	5.28	3,298	17,413	185,150	May 29 04:30 PM
Pham Quang X	CEO and Chairman	May 28 '26	Sale	4.93	2,989	14,736	182,161	May 29 04:30 PM
Pham Quang X	CEO and Chairman	May 22 '26	Sale	5.69	1,165	6,629	194,924	May 26 09:06 PM
Quang X. Pham	Officer	May 11 '26	Proposed Sale	5.81	60,000	348,600		May 11 04:37 PM
Szot Matthew K	Chief Financial Officer	Dec 29 '25	Sale	6.97	9,933	69,233	0	Dec 31 04:05 PM
MATTHEW K SZOT	Officer	Dec 29 '25	Proposed Sale	7.41	9,933	73,604		Dec 29 04:25 PM
Szot Matthew K	Chief Financial Officer	Oct 27 '25	Sale	13.99	1,800	25,182	9,933	Oct 28 05:00 PM
Szot Matthew K	Chief Financial Officer	Oct 24 '25	Sale	13.99	1,800	25,182	11,733	Oct 28 05:00 PM
Pham Quang X	CEO and Chairman	Oct 27 '25	Sale	13.99	1,315	18,397	196,089	Oct 28 05:00 PM
Pham Quang X	CEO and Chairman	Oct 24 '25	Sale	14.03	1,129	15,840	197,404	Oct 28 05:00 PM
MATTHEW SZOT	Officer	Oct 27 '25	Proposed Sale	14.13	1,800	25,442		Oct 27 04:27 PM
Quang X. Pham	Officer	Oct 27 '25	Proposed Sale	13.99	1,315	18,397		Oct 27 04:26 PM
Quang X. Pham	Officer	Oct 24 '25	Proposed Sale	14.03	1,129	15,841		Oct 24 05:03 PM
MATTHEW SZOT	Officer	Oct 24 '25	Proposed Sale	13.77	1,800	24,786		Oct 24 04:26 PM
Szot Matthew K	Chief Financial Officer	Oct 13 '25	Sale	14.07	1,800	25,326	13,533	Oct 14 04:05 PM
Szot Matthew K	Chief Financial Officer	Oct 09 '25	Sale	13.99	1,693	23,685	15,333	Oct 14 04:05 PM
Pham Quang X	CEO and Chairman	Oct 13 '25	Sale	14.15	1,800	25,470	198,533	Oct 14 04:05 PM
Pham Quang X	CEO and Chairman	Oct 09 '25	Sale	14.02	1,800	25,236	200,333	Oct 14 04:05 PM
Quang X. Pham	Officer	Oct 13 '25	Proposed Sale	14.15	1,800	25,470		Oct 14 09:44 AM
MATTHEW SZOT	Officer	Oct 13 '25	Proposed Sale	13.62	1,800	24,516		Oct 14 07:41 AM
MATTHEW SZOT	Officer	Oct 09 '25	Proposed Sale	13.96	1,693	23,634		Oct 09 04:23 PM
Quang X. Pham	Officer	Oct 09 '25	Proposed Sale	14.02	1,800	25,228		Oct 09 04:15 PM
Szot Matthew K	Chief Financial Officer	Oct 06 '25	Sale	13.99	107	1,497	17,026	Oct 07 08:22 PM
MATTHEW SZOT	Officer	Oct 06 '25	Proposed Sale	14.18	107	1,517		Oct 06 04:20 PM
Pham Quang X	CEO and Chairman	Oct 02 '25	Sale	14.13	500	7,065	202,133	Oct 03 08:24 PM
Quang X. Pham	Officer	Oct 02 '25	Proposed Sale	14.13	500	7,066		Oct 02 04:06 PM
Szot Matthew K	Chief Financial Officer	Oct 01 '25	Sale	13.99	1,700	23,783	17,133	Oct 01 05:47 PM
Szot Matthew K	Chief Financial Officer	Sep 29 '25	Sale	14.00	100	1,400	18,833	Oct 01 05:47 PM
Pham Quang X	CEO and Chairman	Oct 01 '25	Sale	14.01	881	12,343	202,633	Oct 01 05:46 PM
Pham Quang X	CEO and Chairman	Sep 29 '25	Sale	14.01	419	5,870	203,514	Oct 01 05:46 PM
Quang X. Pham	Officer	Oct 01 '25	Proposed Sale	14.01	881	12,343		Oct 01 04:29 PM
MATTHEW SZOT	Officer	Oct 01 '25	Proposed Sale	13.83	1,700	23,511		Oct 01 04:27 PM
Quang X. Pham	Officer	Sep 29 '25	Proposed Sale	14.01	419	5,870		Sep 29 04:44 PM
MATTHEW SZOT	Officer	Sep 29 '25	Proposed Sale	14.03	100	1,403		Sep 29 04:36 PM
Szot Matthew K	Chief Financial Officer	Sep 25 '25	Sale	14.05	10,900	153,182	18,933	Sep 26 08:36 PM
Szot Matthew K	Chief Financial Officer	Sep 24 '25	Sale	14.00	1,500	20,993	29,833	Sep 26 08:36 PM
Pham Quang X	CEO and Chairman	Sep 25 '25	Sale	14.09	6,790	95,671	203,933	Sep 26 08:35 PM
Pham Quang X	CEO and Chairman	Sep 24 '25	Sale	13.99	2,581	36,108	210,723	Sep 26 08:35 PM
Quang X. Pham	Officer	Sep 24 '25	Proposed Sale	14.09	6,790	95,662		Sep 25 05:05 PM
MATTHEW SZOT	Officer	Sep 25 '25	Proposed Sale	13.78	10,900	150,202		Sep 25 04:19 PM
Quang Pham	Officer	Sep 24 '25	Proposed Sale	13.99	2,581	36,108		Sep 24 05:46 PM
MATTHEW SZOT	Officer	Sep 24 '25	Proposed Sale	13.68	1,500	20,520		Sep 24 04:21 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CVKD

Cadrenal Therapeutics Inc

Upgrade your Finviz experience